×
About 12,703 results

Effects of Breast Cancer Treatments on Cardiovascular Disease Risk Factors
https://www.clinicaladvisor.com/home/topics/oncology-information-center/breast-cancer-treatments-cardiovascular-disease/
Clinical Advisor

Sep 21st, 2022 - The survival rate of women with breast cancer has been steadily increasing each year since 2007. The 5-year survival rate for women with nonmetastatic invasive breast cancer is currently 90%.1 As survival rates have increased, studies have demonstrated that rates of cardiovascular disease in the same population have been increasing as well. This is an important observation, as cardiovascular di...

Multimodal Treatment Linked to 3-Year Overall Survival in Esophageal Cancer
https://www.clinicaladvisor.com/home/topics/gastroenterology-information-center/multimodal-treatment-linked-to-3-year-overall-survival-in-esophageal-cancer/
Clinical Advisor

Sep 20th, 2022 - Multimodality treatment, including a surgical procedure, may be associated with 3-year overall survival in patients with metastatic esophageal cancer, according to a study in Cancers. Researchers conducted a systematic review of published studies on surgical procedures in patients with synchronous metastatic esophageal cancer to assess the long-term outcomes of multimodal treatments. Researcher...

Incidence of Cutaneous T-Cell Lymphoma Up in the US
https://www.clinicaladvisor.com/home/topics/oncology-information-center/incidence-cutaneous-t-cell-lymphoma-up-us/
Clinical Advisor

Sep 13th, 2022 - HealthDay News — The overall incidence of cutaneous T-cell lymphoma (CTCL) increased in the United States from 2000 to 2018, according to a research letter published online in JAMA Oncology. Zhuo Ran Cai, MD, from Stanford University in California, and colleagues describe recent trends in the incidence of histologically confirmed cases of first primary CTCL with malignant behavior and skin as t...

FDA Warns of Rare Cases of Certain Cancers Linked to Breast Implants
https://www.clinicaladvisor.com/home/topics/oncology-information-center/fda-warns-rare-cases-certain-cancers-linked-breast-implants/
Clinical Advisor

Sep 12th, 2022 - HealthDay News — The US Food and Drug Administration on Thursday warned doctors and their patients about rare cases of squamous cell carcinoma and various lymphomas developing in the scar tissue that forms around breast implants. These cancers are different from an earlier FDA warning about . Federal regulators discovered reports of the cancers as part of a routine postmarket review and caution...

Daily Insulin Dose Tied to Cancer Risk in Patients With Type 1 Diabetes
https://www.clinicaladvisor.com/home/topics/diabetes-information-center/type-1-diabetes-information-center/daily-insulin-dose-tied-cancer-risk-patients-with-t1dm/
Clinical Advisor

Aug 1st, 2022 - HealthDay News — Daily insulin dose is associated with cancer risk among individuals with type 1 diabetes, according to a research letter published online in JAMA Oncology. Wenjun Zhong, PhD, from Merck Research Labs in West Point, Pennsylvania, and Yuanjie Mao, MD, PhD, from the Diabetes Institute at Ohio University in Athens, examined the incidence of cancer among individuals with type 1 diab...

A Banana a Day May Keep Upper GI Cancers Away
https://www.clinicaladvisor.com/home/topics/gastroenterology-information-center/banana-a-day-keep-upper-gi-cancers-away/
Clinical Advisor

Jul 26th, 2022 - A supplement containing resistant starch derived from foods such as bananas reduced upper gastrointestinal cancers by more than half. The effect lasted for 10 years after participants stopped taking the supplement, according to findings from a longitudinal study published in Cancer Prevention Research. “We found that resistant starch reduces a range of cancers by over 60%. The effect was most o...

Risk for Cardiovascular Disease Increased for Adult Cancer Survivors
https://www.clinicaladvisor.com/home/topics/cardiovascular-disease-information-center/risk-cardiovascular-disease-increased-adult-cancer-survivors/
Clinical Advisor

Jul 6th, 2022 - HealthDay News — Adult cancer survivors have an increased risk for cardiovascular disease (CVD) compared with those without cancer, independent of traditional CVD risk factors, according to a study published in the Journal of the American College of Cardiology. Roberta Florido, MD, from the Johns Hopkins University School of Medicine in Baltimore, and colleagues examined the risk for CVD in can...

Early-Onset Pancreatic Cancer Increased in White and Hispanic Women
https://www.clinicaladvisor.com/home/topics/gastroenterology-information-center/early-onset-pancreatic-cancer-increased-white-hispanic-women/
Clinical Advisor

Jun 28th, 2022 - Between 1995 and 2018, non-Hispanic White and Hispanic women in the United States experienced the greatest increases in early-onset pancreatic cancer (EOPC) incidence, according to study results published in Gastroenterology. Researchers extracted data from the North American Association of Central Cancer Registries (NAACCR) for the years 1995 to 2018. The NAACCR dataset consists of information...

USPSTF Recommends Against Vitamin E, Beta-Carotene Use for CVD and Cancer Prevention
https://www.clinicaladvisor.com/home/topics/cardiovascular-disease-information-center/uspstf-recommends-against-vitamin-e-beta-carotene-use-for-cvd-and-cancer-prevention/
Clinical Advisor

Jun 28th, 2022 - The US Preventive Services Task Force (USPSTF) has released a final recommendation on the use of vitamin, mineral, and multivitamin supplements to prevent cardiovascular disease (CVD) and cancer. To assess the benefits and harms of vitamin and mineral supplementation in healthy adults to prevent CVD and cancer, the USPSTF reviewed 17,459 unique citations and 379 full-text articles that included...

Healthy Plant-Based Diet May Cut Breast Cancer Risk
https://www.clinicaladvisor.com/home/topics/diet-and-nutrition-information-center/healthy-plant-based-diet-may-cut-breast-cancer-risk/
Clinical Advisor

Jun 14th, 2022 - HealthDay News — Adherence to a healthy plant-based food diet is associated with reduced risk of breast cancer for postmenopausal women, according to a study presented during NUTRITION 2022, the annual meeting of the American Society for Nutrition, held virtually from June 14 to 16. Sanam Shah, MBBS, MPH, from Paris-Saclay University, and colleagues examined the association between long-term ad...

Decreases in Breast, Cervical Cancer Screening From 2018 to 2020
https://www.clinicaladvisor.com/home/topics/oncology-information-center/decreases-in-breast-cervical-cancer-screening-from-2018-to-2020/
Clinical Advisor

Jun 6th, 2022 - HealthDay News — From 2018 to 2020, there were decreases in the prevalence of screening for breast cancer (BC) and cervical cancer (CC), while the increase in stool testing offset the decrease in colonoscopy for colorectal cancer (CRC) screening, according to a study published online in JAMA Network Open. Stacey A. Fedewa, PhD, from the American Cancer Society in Atlanta, and colleagues examine...

Eating Red Meat May Up Colorectal Cancer Risk in Black Women
https://www.clinicaladvisor.com/home/topics/oncology-information-center/eating-red-meat-may-up-colorectal-cancer-risk-in-black-women/
Clinical Advisor

Jun 6th, 2022 - HealthDay News — Unprocessed red meat intake is associated with an increased colorectal cancer (CRC) risk in Black women, according to a study published in of The Journal of Nutrition. Ioanna Yiannakou, RD, MSc, from Boston University School of Medicine, and colleagues prospectively assessed intakes of processed and unprocessed red meat, saturated fatty acids (SFAs), and monounsaturated FAs (MU...

Top April 2022 FDA Approvals
https://www.clinicaladvisor.com/home/topics/practice-management-information-center/top-april-2022-fda-approvals/
Clinical Advisor

May 18th, 2022 - The US Food and Drug Administration (FDA) approved several drugs in April 2022 relevant to conditions often treated my nurse practitioners and PAs. Approvals include treatments for topical rosacea, vulvovaginal candidiasis, pediatric urinary tract infections, and cancer. Zerbaxa® for Pediatric Intra-abdominal, Urinary Tract Infection The FDA has approved Zerbaxa® (ceftolozane and tazobactam) fo...

Recent Cancer Treatment Linked to Worse COVID-19 Outcomes
https://www.clinicaladvisor.com/home/topics/oncology-information-center/recent-cancer-treatment-linked-worse-covid-19-outcomes/
Clinical Advisor

May 11th, 2022 - HealthDay News — Patients diagnosed with cancer more than 1 year ago and those not receiving active treatment are not at heightened risk for worse COVID-19 outcomes than patients without cancer, according to a study published online in PLOS ONE. Youngran Kim, PhD, from The University of Texas Health Science Center at Houston, and colleagues evaluated the association between COVID-19 outcomes an...

Colonoscopy Before Age 50 May Cut Colorectal Cancer Risk in Women
https://www.clinicaladvisor.com/home/topics/oncology-information-center/colonoscopy-before-age-50-may-cut-colorectal-cancer-risk-women/
Clinical Advisor

May 10th, 2022 - HealthDay News — Initiation of lower gastrointestinal endoscopy before 50 years of age is associated with a reduced risk for colorectal cancer in women, according to a study published online in JAMA Oncology. Wenjie Ma, MD, ScD, from Massachusetts General Hospital in Boston, and colleagues examined the association between endoscopy initiation at different ages and the risk for colorectal cancer...

FDA Clears Automated, Wearable 3D Breast Ultrasound Device
https://www.clinicaladvisor.com/home/topics/oncology-information-center/fda-clears-automated-wearable-3d-breast-ultrasound-device/
Clinical Advisor

May 5th, 2022 - The Food and Drug Administration (FDA) has granted 510(k) clearance to ATUSA™, an ultrasound system designed to capture imaging of the breast at the point of care. The ATUSA system includes a 3D ultrasound scanner, a wearable accessory, and a Windows application for automated image acquisition and analysis. In 2 minutes, the portable ATUSA system provides real-time 2D images of the breast tissu...

Trastuzumab Deruxtecan Gets Priority Review for Previously Treated HER2-Mutant Metastatic NSCLC
https://www.pulmonologyadvisor.com/home/topics/lung-cancer/trastuzumab-deruxtecan-gets-priority-review-for-previously-treated-her2-mutant-metastatic-nsclc/
Pulmonology Advisor

May 4th, 2022 - The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for fam-trastuzumab deruxtecan-nxki (Enhertu®) for the treatment of adults with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have a HER2 (ERBB2) mutation and who have received a prior systemic therapy. The sBLA is supported by data from the ...

Ovarian Cancer is Not a Silent Killer – Recognizing Its Symptoms Could Help Reduce Misdiagnosis and Late Detection
https://www.clinicaladvisor.com/home/topics/oncology-information-center/ovarian-cancer-reducing-misdiagnosis-late-detection/
Clinical Advisor

Apr 26th, 2022 - Ovarian cancer is the of gynecologic tumors. Fewer than 40% of those diagnosed with ovarian cancer are cured, and approximately in the US die from the disease every year. For the past 25 years, scientists have tried to identify a screening test to detect ovarian cancer in its earliest stages, when the . Unfortunately, multiple with hundreds of thousands of participants have failed to identify a...

Vitamin D Level, Race/Ethnicity Tied to Breast Cancer Risk
https://www.clinicaladvisor.com/home/topics/oncology-information-center/vitamin-d-level-race-ethnicity-tied-breast-cancer-risk/
Clinical Advisor

Apr 25th, 2022 - HealthDay News — Sufficient circulating concentrations of vitamin D may protect against breast cancer in Hispanic/Latina women, according to a study published online in Cancer. Katie M. O’Brien, PhD, from the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina, and colleagues examined the association between vitamin D levels and breast cancer among 290 ...

Trial Evaluating Tiragolumab Combo for Extensive-Stage SCLC Misses Endpoint
https://www.pulmonologyadvisor.com/home/topics/lung-cancer/trial-evaluating-tiragolumab-combo-for-extensive-stage-sclc-misses-endpoint/
Pulmonology Advisor

Apr 13th, 2022 - A phase 3 study evaluating tiragolumab in combination with atezolizumab (Tecentriq®) and chemotherapy (carboplatin and etoposide) as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) did not meet its coprimary endpoint. Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and suppresses the immune response...